Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

　　2024年1月12日，在《Frontiers in Oncology》上發(fā)表的論文，標題為：“Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer”

　　使用締一生物國內(nèi)總代理的德國MB Venor GeM-qEP kit from Minerva Biolabs。